Rehovot, Israel – April 17, 2014 – Evogene Ltd. (NYSE, TASE: EVGN), a leading plant
genomics company specializing in enhancing crop productivity for the food, feed and biofuel
industries, announced today that it will release its financial results for the first quarter of 2014
on Wednesday, May 7, 2014.
On the day of the announcement, the Company’s management will host a conference call to
discuss the results at 09:30 AM Eastern time, 16:30 Israel time. To access the conference call, please dial 1-888-668-9141 toll-free from the United States, or +972-3-918-0609 internationally. Access to the call will also be available via live webcast through the Company’s website at www.evogene.com.A replay of the conference call will be available approximately three hours following the completion of the call. To access the replay, please dial 1-888-782-4291 toll free from the United States, or +972-3-925-5904 internationally. The replay will be accessible through May 9, 2014, and an archive of the webcast will be available on the Company’s website through May 17, 2014.
-xxx-
About Evogene Ltd.
Evogene (NYSE, TASE: EVGN) is a plant genomics company, utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on a deep scientific understanding of plant genomics and proprietary computational capabilities. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals and seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.comThis press release contains “forward-looking statements” relating to future events. These statements may be identified by words such as “may”, “expects”, “intends”, “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from whatis expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene’s control, including, without limitation, those risk factors contained in Evogene’s reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Contact:
Karen Mazor, Evogene
Director, Public and Investor Relations
T: +972 54 22 88 039
karen.mazor@evogene.com
